Open Collections

UBC Faculty Research and Publications

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? Fingrut, Warren; Davis, Wendy; McGinnis, Eric; Dallas, Karen; Ramadan, Khaled; Merkeley, Hayley; Leitch, Heather; Abou Mourad, Yasser; Cassaday, Ryan D.; Ross, Camilla; Léger, Chantal

Abstract

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.

Item Metadata

Title
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Creator
Fingrut, Warren; Davis, Wendy; McGinnis, Eric; Dallas, Karen; Ramadan, Khaled; Merkeley, Hayley; Leitch, Heather; Abou Mourad, Yasser; Cassaday, Ryan D.; Ross, Camilla; Léger, Chantal
Contributor
St. Paul's Hospital (Vancouver, B.C.).; University of British Columbia. Division of Hematology. Department of Medicine
Publisher
Multidisciplinary Digital Publishing Institute
Date Issued
2020-12-31
Description
Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.
Subject
inotuzumab ozogamicin; cd22; acute lymphoblastic leukemia; flow cytometry; immunotherapy
Genre
Article
Type
Text
Language
eng
Date Available
2021-03-02
Provider
Vancouver : University of British Columbia Library
Rights
CC BY 4.0
DOI
10.14288/1.0396006
URI
http://hdl.handle.net/2429/77423
Affiliation
Medicine, Faculty of; Alumni; Non UBC
Citation
Current Oncology 28 (1): 252-259 (2021)
Publisher DOI
10.3390/curroncol28010027
Peer Review Status
Reviewed
Scholarly Level
Faculty
Rights URI
https://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

CC BY 4.0